imnp target at 6$, what is in for ico?if imnp target price is at 6$ what is in for ico presently at 0.075 ?
Immune Pharmaceuticals Research Coverage Started at MLV & Co. (IMNP)
Posted by Pezhman Azimi on Jun 12th, 2015 //
Investment analysts at MLV & Co. initiated coverage on shares of Immune Pharmaceuticals (NASDAQ:IMNP) in a note issued to investors on Thursday. The firm set a “buy” rating and a $6.00 price target on the biopharmaceutical company’s stock. MLV & Co.’s target price would indicate a potential upside of 181.69% from the company’s current price.
Separately, analysts at Chardan Capital raised their price target on shares of Immune Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Monday, May 18th.
Immune Pharmaceuticals (NASDAQ:IMNP) traded up 0.95% on Thursday, hitting $2.13. The stock had a trading volume of 156,367 shares. Immune Pharmaceuticals has a 52 week low of $1.50 and a 52 week high of $4.25. The stock has a 50-day moving average of $2. and a 200-day moving average of $1.. The company’s market cap is $52.51 million.
Immune Pharmaceuticals (NASDAQ:IMNP) last announced its earnings results on Monday, May 18th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.05. On average, analysts predict that Immune Pharmaceuticals will post $-1.04 earnings per share for the current fiscal year.
Immune Pharmaceuticals Inc (NASDAQ:IMNP), formerly EpiCept Corporation is a clinical stage biopharmaceutical company. The Company specializes in the development and commercialization of targeted therapeutics, including monoclonal antibodies (mAbs), nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals